Rheumatoid arthritis Archives -

ICER says ‘marginal’ benefits for AbbVie’s new RA drug

https://pharmaphorum.com/news/icer-says-marginal-benefits-for-abbvies-new-ra-drug/

Celltrion gears up for subcutaneous infliximab launch in Europe

https://pharmaphorum.com/views-analysis-market-access/celltrion-gears-up-for-subcutaneous-infliximab-launch-in-europe/

Improving medicines adherence with VR

https://pharmaphorum.com/views-analysis-digital/improving-medicines-adherence-vr/

North American Prefilled Syringes Market to achieve 10% CAGR up to 2025

https://pharmaphorum.com/partner-content/north-american-prefilled-syringes-market-to-achieve-10-cagr-up-to-2025/

Gilead invests $5.1bn in Belgian biotech Galapagos

https://pharmaphorum.com/news/gilead-invests-5-1bn-in-belgian-biotech-galapagos/

GSK takes aim at RA market, pitting otilimab against Pfizer and Sanofi rivals in phase 3

https://pharmaphorum.com/news/gsk-takes-aim-at-ra-market-pitting-otilimab-against-pfizer-and-sanofi-rivals-in-phase-3/

AbbVie makes case for Humira follow-on upadacitinib at EULAR

https://pharmaphorum.com/news/abbvie-makes-case-for-humira-follow-on-upadacitinib-at-eular/

Patients switch to lower dose of Pfizer’s RA pill after safety signal

https://pharmaphorum.com/news/patients-switch-to-lower-dose-of-pfizers-ra-pill-after-safety-signal/

AbbVie’s JAK inhibitor upadacitinib gets Priority Review

https://pharmaphorum.com/news/abbvies-jak-inhibitor-upadacitinib-gets-priority-review/

Search